



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
 (Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**  
**FOR THE PERIOD ENDED 30 SEPT 2010**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 9/30/2010 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 9/30/2009 RM'000	CURRENT YEAR TO DATE 9/30/2010 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 9/30/2009 RM'000
Revenue	34,464	32,188	99,242	93,916
Cost of Sales	(18,184)	(17,125)	(55,821)	(47,268)
<b>Gross Profit</b>	<b>16,280</b>	<b>15,063</b>	<b>43,421</b>	<b>46,648</b>
Other operating income	103	215	504	633
Distribution costs	(3,176)	(2,778)	(8,665)	(8,490)
Administration expenses	(2,405)	(2,364)	(6,737)	(7,067)
Other operating expenses	(571)	(857)	(1,689)	(2,088)
<b>Profit from operations</b>	<b>10,231</b>	<b>9,279</b>	<b>26,834</b>	<b>29,636</b>
Finance costs	(10)	(11)	(32)	(31)
<b>Profit before taxation</b>	<b>10,221</b>	<b>9,268</b>	<b>26,802</b>	<b>29,605</b>
Taxation	(2,602)	(2,339)	(6,747)	(7,216)
<b>Profit after tax for the period</b>	<b>7,619</b>	<b>6,929</b>	<b>20,055</b>	<b>22,389</b>
Other comprehensive income for the period, net of tax	-	-	-	-
<b>Total comprehensive income for the period</b>	<b>7,619</b>	<b>6,929</b>	<b>20,055</b>	<b>22,389</b>
<b>Profit attributable to:</b>				
Owners of the parent	7,619	6,929	20,055	22,389
Non-controlling interest	-	-	-	-
	<b>7,619</b>	<b>6,929</b>	<b>20,055</b>	<b>22,389</b>
<b>Total comprehensive income attributable to :</b>				
Owners of the parent	7,619	6,929	20,055	22,389
Non-controlling interest	-	-	-	-
	<b>7,619</b>	<b>6,929</b>	<b>20,055</b>	<b>22,389</b>
Earnings per share (sen)				
Basic (based on weighted average)	5.49	4.99	14.45	16.13
Diluted (based on weighted average)	5.49	4.99	14.45	16.13

(The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 30 SEPT 2010

	AS AT END OF CURRENT PERIOD 30/9/2010 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2009 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	92,213	74,840
<b>Total non-current assets</b>	<u>92,213</u>	<u>74,840</u>
Inventories	33,243	36,353
Trade & Other Receivables	36,428	34,086
Related Company	860	1,023
Current tax assets	-	63
Cash & Cash Equivalents	24,957	26,999
<b>Total current assets</b>	<u>95,488</u>	<u>98,524</u>
<b>Total Assets</b>	<u><u>187,701</u></u>	<u><u>173,364</u></u>
<b>EQUITY</b>		
Share Capital	69,739	69,739
Reserves	80,394	74,577
Treasury Shares	(1,578)	(1,578)
<b>Total Equity</b>	<u>148,555</u>	<u>142,738</u>
<b>LIABILITIES</b>		
Deferred Tax Liability	4,422	4,466
Term Loan	12,499	9,175
<b>Total non-current liabilities</b>	<u>16,921</u>	<u>13,641</u>
Trade & Other Payables	10,949	9,052
Amount due to related company	975	1,016
Provision	444	666
Taxation	1,523	-
Term Loan	8,334	6,251
<b>Total current liabilities</b>	<u>22,225</u>	<u>16,985</u>
<b>Total Liabilities</b>	<u>39,146</u>	<u>30,626</u>
<b>Total Equity &amp; Liabilities</b>	<u><u>187,701</u></u>	<u><u>173,364</u></u>
<b>Net assets per share (RM)</b>	<b>1.07</b>	<b>1.02</b>

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW**  
**FOR THE PERIOD ENDED 30 SEPT 2010**

	30 Sept 10 RM '000	30 Sept 2009 RM '000
Cash generated from operations:	32,898	22,125
Income taxes paid	(5,207)	(5,841)
<b>Net cash generated from operating activities</b>	<b>27,691</b>	<b>16,284</b>
<b>Net cash used in investing activities</b>	<b>(20,911)</b>	<b>(8,793)</b>
Cash generated from financing activities		
Dividend paid	(14,229)	(9,718)
Drawdown of term loan	5,407	-
<b>Net cash used in financing activities</b>	<b>(8,822)</b>	<b>(9,718)</b>
<b>Net (decrease) / increase in cash and cash equivalents</b>	<b>(2,042)</b>	<b>(2,227)</b>
Cash and cash equivalents as at 1 Jan	26,999	18,424
<b>Cash and cash equivalents as at 30 Sept (I)</b>	<b>24,957</b>	<b>16,197</b>

(I) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	7,440	2,847
Fixed deposits placed with licensed financial institutions	17,517	13,350
	24,957	16,197

(The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)